We examined the effect of cytokines on basal and agoniststimulated release of von Willebrand factor (vWf) by human endothelial cells. Treatment of endothelial cells for up to 48 hours with human recombinant or purified interleukin 1 (IL-1) or human recombinant tumor necrosis factor-a (TNF-a) did not significantly affect constitutive secretion of vWf or intracellular levels of vWf, although basal prostacyclin (PGI,) production was markedly enhanced. In contrast, both IL-1 and TNF-a modulated vWf release in response to thrombin or phorbol ester. Pretreatment of endothelial cells for 2 hours with either cytokine enhanced by up to threefold the stimulatory effect of a subsequent 60-minute exposure to thrombin. Addition of cycloheximide (5 pg/mL) HE ACUTE INFLAMMATORY response to tissue T injury caused by infection or trauma consists of several biochemical and clinical alterations, including fever, leukocytosis, increased synthesis of hepatic acute phase proteins such as C-reactive protein (CRP), and changes in plasma metal and steroid concentration^."^ Considerable evidence now shows that many of the aspects of the acute phase response can be attributed to release of a family of monocyte-derived peptides, which include interleukin (IL-1), IL-6, and tumor necrosis factor (TNF).'.' ' We recently showed that in addition to the welldocumented components of the acute phase response, a significant elevation occurs in the levels of plasma von Willebrand factor during the course of a range of bacterial, viral, and parasitic infections." von Willebrand factor (vWf) is a large adhesive glycoprotein, circulating in the plasma as a series of heterogeneous multimers of molecular weights 0.4 to 20 x lo6, which plays an important role in the interaction of platelets with the blood vessel wall, as well as serving as the stabilizing carrier protein for coagulation factor VIII.'2-15 The predominant site of vWf synthesis is the vascular endothelium,16 which is the major source of plasma vWf in v~v o . '~ Cultured vascular endothelial cells secrete vWf constitutively.I6 In addition to this continuous release of vWf, rapid secretion of preformed vWf, localized in intracellular storage organelles termed Weibel-Palade b o d i e~, '~~'~ can be provoked in vivo and in vitro by a number of agents, including thrombin, 4-phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23 187, fibrin, and We have proposed'' that the acute and transient elevations of plasma vWf levels observed during infection may be the result of modulation of either constitutive or stimulated endothelial vWf release by circulating mediators of the acute phase response, such as IL-1 or TNF. Cytokines induce significant changes in endothelial cell function, including stimulation of prostacyclin (PGI,) s y n t h e~i s ,~~,~~ induction of tissue factor procoagulant activity" and enhancement of leukocyte adhesion to endothelial cells.29 Evidence regarding the effect of cytokines on vWf release from endothelial cells is conflicting, however. De Groot et a13' reported that pretreatment of endothelial cells for 12 to 48 hours with recombinant human or murine IL-1 decreased both constitutive and stimulated release of vWf, with a concomitant reduction in the amount of vWf stored in the Weibel-Palade organelles, whereas Zavoico et a131 failed to observe any effect of prolonged IL-1 treatment on either basal or agonist-induced secretion of vWf. In contrast, Giddings and reported that vWf release from endothelial cells incubated for up to 4 hours with purified human IL-1 was significantly higher than release from control cells. Similar observations were also independently reported by two other groups of investig a t o r~.~~.~~ Because such discrepancies may relate to the conditions of the individual studies and especially to the time of incubation with IL-1, we investigated further the effect of cytokines on release of vWf. In particular, we assessed the effect of different cytokine preparations and different cytokine treatment times on both constitutive and agonist-stimulated secretion of vWf by human vascular endothelial cells.
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MATERIALS AND METHODS
Endothelial cells from human umbilical veins were isolated and cultured as described by Jaffe et Except where noted, for our experiments first-passage endothelial cells were harvested with 0.1% trypsin/0.02% EDTA and plated in 16-mm diameter wells (GIBCO, Uxbridge, England) at approximately 8 x lo4 cells per well, in Medium 199 supplemented with 20% calf serum, 90 pg/mL heparin, and 20 pg/mL endothelial cell growth supplement (ECGS) (prepared from bovine brain36). Visually confluent monolayers were formed after overnight incubation.
At confluence, culture medium was removed from each well and replaced with Medium 199 containing 20 mmol/L HEPES and 20% calf serum, with or without the appropriCell culture.
Release of vWf.

REGULATION BY CYTOKINES OF vWF
ate agent. Cell supernatants were sampled at various time intervals. In certain experiments, endothelial cells were then transferred to serum-free Medium 199 containing 20 mmol/L HEPES for 60 minutes and subsequently incubated at 37OC in the above medium, with or without agonist. Cell supernatants were sampled after another 60 minutes.
Release of vWf into the cell supernatants was measured by an enzyme-linked immunosorbent assay (ELISA) using a modification of the technique described by Short et a].'' Mouse monoclonal anti-vWf CLBRAg35, used as the solid phase, was a gift from Dr J.A. Van Mourik." Samples were incubated for 1 hour at 20° to 22OC with the coating antibody, after which rabbit polyclonal antihuman vWf (Dako, High Wycombe, England) was added, followed by goat anti-rabbit IgG conjugated to alkaline phosphatase (Sigma, Poole, UK). 4-Methylumbelliferyl phosphate (Koch-Light, Haverhill, England) was used as the substrate, and the fluorescence was read in a Titertek Fluoroskan. Dilutions of pooled normal human plasma containing 2.4 IU/mL vWf (by refrence to an international standard provided by Dr T. Barrowcliffe, National Institute for Biological Standards and Control, UK) were used to construct standard curves. The lower limit of detection was 2.5 x IU/mL.
After cytokine treatment as described and removal of cell supernatants, the endothelial cell monolayers were washed twice with serum-free Medium 199 and lysed with 0.1% Triton X-100 (Sigma) in phosphate-buffered saline (PBS). Levels of vWf in cell lysates were assayed by ELISA as described.
Measurement of PGI,. Production of PGI, was measured using a specific radioimmunoassay for 6-keto-prostaglandin F,,, the stable hydrolysis product of PG12." Cellular protein synthesis after cytokine treatment was assessed using incorporation of 'H-leucine, as described by Morgan."' As a positive control a cytotoxic anti-MHC class I antibody was used (MAS1 14b, Seralab, Crawley, UK).
RNA was extracted by a modification of the method of Auffray and Ro~geon.~' Seven milliliters 3 mol/L Li C1, 6 mol/L urea at 4OC was added to the culture surface of a 75-cm2 flask of cells and left on ice for 5 minutes. The resulting lysate was stored at 4OC overnight to precipitate the RNA, which was collected by centrifugation, redissolved in 10 mmol/L Tris-HC1 (pH 7.5) containing 0.5% sodium dodecyl sulfate (SDS), and incubated for 30 minutes at 37OC with .proteinase K (100 pg/mL). The RNA was then extracted three times with phenol/chloroform (I:]), precipitated in ethanol, and redissolved in water.
Total RNA, 10 pg per lane, was electrophoresed in denaturing 1.1% agarose/formaldehyde gels4, and transferred overnight using 20 x SSC (3 mol/L NaCI, 300 mmol/L sodium citrate) to GeneScreen membranes (NEN-Dupont, Stevenage, UK). The RNA was fixed to the membrane by ultraviolet cross-linking at 254 nm, 120,000 pJ, followed by baking at 8OoC for 2 hours. RNA was prehybridized for 2 hours at 65OC and then hybridized overnight, at 45OC when cDNA probes were used and at 65OC when anti-sense RNA probes were used. Prehybridization and hybridization were both carried out in 50% formamide, 50 mmol/L sodium phosphate, 5 x SSC, 1% SDS, 5 x Denhardt's solution, 200 pg/mL denatured sheared salmon sperm DNA, and 100 pg/mL yeast tRNA. Blots were then washed twice, for 30 minutes each time, in 0.1 x SSC and 0.5% SDS at 55OC for cDNA probe hybridization and at 75OC for anti-sense RNA probe hybridization. The membrane was then exposed to Kodak XARS film (Hemel Hempstead, UK) at -7OOC with image intensifying screens. Filters were stripped of the previously hybridized probe by washing at 8OoC for 30 minutes in 70% formamide, 1% SDS.
Measurement of intracellular vWf levels.
Cytotoxicity assay.
RNA extraction, electrophoresis. and hybridization.
The human cDNA probe for vWf (pvWf 1,100) used was a gift from Dr H. Pannekoek of the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Am~terdam.~' It was labeled with 32P-dATP (3,000 Ci/mmol/L; Amersham, UK) by random primer extensi0n.4~ Human cDNA for tissue factor representing the first 1,350 base pairs (bp) of the full-length CDNA;~ a gift from Genentech, San Francisco, CA, was subcloned into pSP64 and linearized with SacI. Single-stranded, anti-sense RNA probes were synthesized with SP6 RNA polymerase using "P-dUTP (800 Ci/mmol/L; Amersham) as recommended by Promega Biotec. A 1,350 bp Psi1 fragment of a murine a-actin cDNA was subcloned into pGEMl (Promega Biotec). This was linearized with Hind 111, and single-stranded, anti-sense, 32P-labeled RRA probes were made as described but with T7 RNA polymerase.
Experiments were performed with (a) human recombinant IL-la (HRIL-la) (provided by John Budd, Roche Products, Welwyn, England), 700 U/pmol, 4 x lo7 U/mg; (b) HRIL-I@ (Genzyme), 1,750 U/pmol, lo8 U/mg; (c) purified IL-1 obtained from Staphylococcus albus-stimulated human monocytes (Ultrapure IL-1, Genzyme: HN IL-1), 1.4 x lo5 U/pmol, 8 x lo9 U/mg; (d) purified human placental IL-I (gift from Dr R. B~n n i n g~~: HPIL-I) 2,500 LAF U/mL; and (e) HRTNF-a (Genzyme), 720 U/pmol, 2 x lo7 U/mg. Human a-thrombin, cycloheximide, polymyxin B, and PMA were purchased from Sigma; L-[4,5-3H(N)]-leucine (1 .O mCi/mL, 5.0 Ci/mmol) was from NEN.
Materials.
RESULTS
Eflect of cytokines on constitutive release of v WJ
Treatment of endothelial cells for 24 hours with recombinant IL-la had no significant effect on constitutive release of vWf into the culture medium (Fig 1) . In contrast, basal synthesis of PGI, increased in the presence of IL-1 in a dose-dependent manner (Fig 1) . Similarly, when endothelial cells were treated for 2 to 24 hours with a fixed dose (10 U/mL) of either placental IL-1 (HPIL-1) or recombinant IL-la, no difference was detected in the amount of vWf secreted by control and cytokine-treated cells (Fig 2a) . In the same experiment, an increase in basal PGI, synthesis was observed as early as 6h after addition of IL-1 (Fig 2b) . ( Fig 3) . In other experiments, no effect of any human IL-1 preparation tested (at 520 U/mL) on constitutive secretion of vWf was detected even after 48-hour treatment (not shown).
Incubation of endothelial cells for 24 hours with recombinant TNF-a, at doses up to 100 U/mL, also failed to alter release of vWf, although synthesis of PGI, was again significantly stimulated a t all concentrations of TNF-a (Table 1) . Moreover, addition of a combination of submaximal doses of recombinant TNF-a and recombinant IL-la was without effect on basal secretion of vWf although it had an additive effect on PGI, release (Table 1) .
If primary rather than subcultured endothelial cells were used, similar increases in basal PGI, production were observed after treatment with IL-1 for I 24 hours, again with no detectable effect on constitutive release of vWf (not shown).
Effect of cytokines on stimulated release of vWJ
Stimulation of endothelial cells with thrombin (0.1 to 10 U/mL) induced release of vWf into the culture medium at levels of 2 to 20 mU/ 1 O5 cells in 60 minutes. Preincubation of endothelial cells for 2 hours with recombinant IL-I@ increased the amount of vWf released by the cells in response to a subsequent 60-minute exposure to 0.1 to 10 U/mL thrombin, with a substantial elevation in the maximal secretory response induced by thrombin (Fig 4) . Similar results were obtained using purified rather than recombinant IL-1. The extent of this enhancement of vWf release in response to a subsequent stimulus was dependent on the dose of IL-1 used, reaching a maximum with 30 U/mL IL-1 (not shown), and also on the time of pretreatment with IL-1, reaching a maximum with a preincubation time of 2 hours. Thereafter, vWf release in response to thrombin decreased to control levels within 4 hours (Fig 5) . Addition of cycloheximide (5 pg/mL) during the pretreatment period completely abolished the effect of the cytokine (Fig 5 ) . IL-1 were not synergistic ( Table 2) . Pretreatment of endothelial cells with IL-1 or TNF-a also increased the amount of vWf secreted in response to a subsequent challenge by PMA (1 to 100 ng/mL), with a similar enhancement of the maximal secretory response (not shown). In contrast, if the cytokine pretreatment time was extended to 24 hours, significant suppression of thrombinstimulated vWf release was observed (Figs 5 and 6 ). The extent of the decrease in stimulated vWf release was dependent on the dose of cytokine (Fig 7) . Again comparable results were obtained using PMA as the stimulus for release of vWf (not shown).
Treatment of HUVEC with IL-1 for 2 to 24 hours did not significantly alter the cellular levels of vWf: eg, in three similar experiments, the intracellular levels of vWf after 24-hour incubation with HRIL-ID were 14.34 2 4.07 mU/105 cells, as compared with 11.24 2.37 mU/105 cells in control cultures (means f SD, n = 18).
As described, treatment with IL-1 and TNF-a significantly enhances basal synthesis of PGI,. In addition, cytokine pretreatment markedly increased PGI, synthesis in response to a subsequent dose of thrombin, although the pattern of this enhancement differed strikingly from the effect of cytokines on stimulated release of vWf. As shown in Fig 8, 2 -hour pretreatment of endothelial cells with IL-1 had no significant effect on thrombin-induced PGI, synthesis. An increase in the amount of PGI, synthesized was observed only after 6-
Eflect of IL-1 on intracellular levels of vWf:
Ejiect of cytokines on stimulated PCI, synthesis. (Table 3 ). Higher doses of TNF-a (50 to 100 U/mL), but not of IL-1, significantly stimulated protein synthesis, an effect observed more clearly if 'H-leucine incorporation was measured for the 24-hour period subsequent to cytokine treatment (Table 3 ). The effects of cytokines on stimulated release of vWf and PGI, were not altered when 10 pg/mL polymyxin B was added (not shown).
Northern blot analysis (Fig 9) shows an mRNA transcript for vWf of approximately 9 kilobases, which is in agreement with the original Effect of cytokines on v Wf mRNA. de~cription.~' Stimulation of endothelial cells with HRIL-l p for 2 or 24 hours had no effect on the level of vWf or a-actin mRNAs. Substantial induction of procoagulant tissue factor mRNA was effected by the 2-hour IL-1 treatment, however, but this response had decayed by 24 hours.
DISCUSSION
The host response to acute inflammation is characterized by a coordinated series of metabolic reactions, predominantly, although not exclusively, within the liver. In a variety of experimental systems, monocyte-derived products have been shown to elicit many of these acute phase reactions. For example, TNF-a or IL-1 regulates the synthesis of positive (serum amyloid A) and negative (albumin) acute phase reactant^.^.^' We recently showed that circulating vWf, a plasma protein of nonhepatic origin, is significantly increased during the acute phase response." Exposure to cytokines is known to regulate the release of several other biologically active mediators from endothelium, including PGI,,26 tissue plasminogen activator and plasminogen activator inhibitor-I." and 11.-1 itself," but reports describing their effects on endothelial vWf release arc contradictory."' ''
We show that treatment of HUVEC for up to 48 hours with human recombinant TNF-a or various human IL-I preparations (purified or recombinant) has no significant effect on cumulative constitutive release of vWf or on intracellular levels of vWf. I n the same experiments, each cytokinc preparation markedly enhanced synthesis of PGI,.
These observations agree with the recent results of 7avoico et al." who also failed to observe any effect of HRIL-I on constitutive vWf secretion under conditions in which PGI, synthesis was significantly increased. These results are at variance. however. with previous reports'?'" in which a transient two-to fourfold elevation of vWf release occurred when endothelial cells were treated with purified human 11.-1. in the absence of other agonists. for 30 minutes to 4 hours. This release appeared to result from granular secretion because it was accompanied by loss of the granular fluorescent locali7ation of vWf" and was not sensitive to cycloheximide pretreatment." Wecannot explain the discrep ancy bctween this and our own results. although further inconsistencies exist in the available data. were not the result of contamination with bacterial lipopolysaccharide and arc not attributable to endothelial cell injury.
Northern blot analysis showed no detectable alteration in vWf mRVA levels after either 2-or 24-hour stimulation by II.-I. De Groot et aI"' reported a modest reduction in vWf mRNA after 24-hour IL-I treatment. whereas Reinders et al" reported no change in vWf mRNA levels up to 48 hours after PIMA stimulation. Our results. however. mainly show that at 2 hours, when vWf secretion was substantially enhanced in response to an agonist and easily detectable elevation of another mRNA (tissue factor) was observed. vWf mRNA levels were not changed.
Because cytokine pretreatment for 2 to 4 hours increases the maximal ability of an agonist to secrete vWf. while steady-state levels of vWf mRNA and constitutive vWf release remain unchanged. we conclude that the cytokines act by facilitating the transduction pathways that couple agonist-binding to the exocytotic event causing secretion of granular vWf. These pathways (like those utilized by activated cytokine receptors) are largely unknown. Their definition and their links with the pathways leading to stimulation of PGI, synthesis require further study.
The time courses of cytokine-induced changes in vWf secretion and PGI, synthesis are clearly different. Rossi et al and Dejana et al"." previously reported that basal PGI, synthesis wasenhanced after pretreatment with cytokines for 24 hours. We have extended these results and confirmed the recent findings of 7~voico et al'' by showing that PGI, release, either basal or in response to an agonist (Fig 8) , is significantly enhanced after 6 hours of treatment with cytokine, and this enhancement is greater after 24 hours.
Earlier studies have led to conclude that cytokine treatment of endothelial cells alters their properties in a procoagulant direction, owing to the reciprocal actions of IL-1 or TNF-(Y on the procoagulant and fibrinolytic activities of endothelial cell^,*^.^'*^^ and our own results also indicate that an increased ability to secrete vWf may accompany or precede these changes. At later times, however, when vWf release is unaltered or depressed and PGI, release is enhanced, an antithrombotic balance is restored.
This investigation was initiated by our finding that vWf is elevated as part of the acute phase response in humans," which led us to propose that IL-1 mediates vWf release. This hypothesis is in part substantiated by the present results. We have been able to discern effects of IL-1 or TNF-a on agonist-stimulated vWf secretion but were unable to detect direct effects of the cytokines alone on vWf release. More recently, several of the actions of IL-1 were shown to result from stimulated release of IL-6 (eg, recombinant IL-6 regulates the transcriptional activation of a set of acutephase genes in a human hepatoma cell line9 and stimulates CRP synthesis in cultured human hepatocytes''). Endothelial cells produce IL-6,56*57 which is stimulated within 4 hours by pretreatment with IL-1 .56 Although exogenous IL-6 did not alter endothelial cell production of PGI, or procoagulant it will be of interest to determine whether IL-6 affects vWf release. 
